Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Robert K. Hills et al.|Blood|2018Cited by 1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H. Petersdorf, Frederick R. Appelbaum, Kenneth J. Kopecky et al.|Blood|2013Cited by 632
SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLMay S.K. Sutherland, Julie A. McEarchern, Roland B. Walter et al.|Blood|2013Cited by 385
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisSarah Buckley, Roland B. Walter|Haematologica|2017Cited by 282